Manufacturers of rinse-off and leave-on cosmetics would have four years and six years, respectively, to comply with ECHA’s proposed restriction on intentionally added microplastics, efforts that ECHA estimates would cost industry around $1.1bn and $7.4bn over 20 years. Microbeads in rinse-off exfoliating/cleansing cosmetics, largely phased out already, would be banned without delay.
The European Chemicals Agency’s proposed restriction on intentionally added microplastics under the EU’s REACH program is comprehensive and far-reaching, confirming that the cosmetics industry had good reason for apprehension going into the new year.
Announced Jan. 30, the proposal calls for the elimination of manufactured microplastic use across a range of industries, including...
What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.
While FDA fully supports the recent roadmap to reduce and eliminate animal testing, animal tests are still necessary for assessing systemic effects, says Jacqueline Corrigan-Curay, acting director for CDER, during a House Energy and Commerce Health Subcommittee hearing.
The European Commission’s Simplification Omnibus published July 8 is ‘step in right direction’ for streamlining processes and providing more legal certainty and predictability for regulations addressing cosmetics, says Cosmetics Europe.
White House announces president extends deadline he set in April for other countries to make new tariff deals from July 9 to Aug. 1, when the administration will start sending letters warning other countries that higher tariffs could take effect.
What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.
FDA would receive more funding for fiscal year 2026 in the Senate appropriations bill than its House counterpart, including $10m for unannounced foreign inspections.
While FDA fully supports the recent roadmap to reduce and eliminate animal testing, animal tests are still necessary for assessing systemic effects, says Jacqueline Corrigan-Curay, acting director for CDER, during a House Energy and Commerce Health Subcommittee hearing.
